title: Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients.
abstract: BACKGROUND
  Circulating adipocyte fatty acid-binding protein (FABP4) levels are considered to be a link between obesity, insulin resistance, diabetes, and cardiovascular (CV) diseases. In vitro, FABP4 has exhibited cardiodepressant activity by suppressing cardiomyocyte contraction. We have explored the relationship between FABP4 and the N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) as a clinical parameter of heart failure (HF).
  
  
  METHODS
  We included 179 stable HF patients who were referred to a specialized HF unit, 108 of whom were prospectively followed for up to 6 months. A group of 163 non-HF patients attending a CV risk unit was used as the non-HF control group for the FABP4 comparisons.
  
  
  RESULTS
  In the HF patients, FABP4 and NT-proBNP were assayed, along with a clinical and functional assessment of the heart at baseline and after 6 months of specialized monitoring. The FABP4 levels were higher in the patients with HF than in the non-HF high CV risk control group (p<0.001). The FABP4 levels were associated with the NT-proBNP levels in patients with HF (r=0.601, p<0.001), and this association was stronger in the diabetic patients. FABP4 was also associated with heart rate and the results of the 6-minute walk test. After the follow-up period, FABP4 decreased in parallel to NT-proBNP and to the clinical parameters of HF.
  
  
  CONCLUSIONS
  FABP4 is associated with the clinical manifestations and biomarkers of HF. It exhibits a parallel evolution with the circulating levels of NT-proBNP in HF patients.
authors: Unitat de Recerca en Lípids i Arteriosclerosi, Hospital Universitari Sant Joan, CIBERDEM, Reus, Spain.
authors: Anna
authors: A
authors: Cabré
authors: Pilar
authors: P
authors: Valdovinos
authors: Iolanda
authors: I
authors: Lázaro
authors: Gil
authors: G
authors: Bonet
authors: Alfredo
authors: A
authors: Bardají
authors: Lluís
authors: L
authors: Masana
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D018450:Disease Progression; D050556:Fatty Acid-Binding Proteins / Q000097:blood*; D005260:Female; D006333:Heart Failure / Q000097:blood*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood*; D011446:Prospective Studies
chemical_list: D015415:Biomarkers; C493410:FABP4 protein, human; D050556:Fatty Acid-Binding Proteins; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain
references: PLoS One. 2011 Apr 28;6(4):e19115
references: 21552513
references: Circ Res. 2009 Aug 14;105(4):326-34
references: 19608978
references: Science. 1996 Nov 22;274(5291):1377-9
references: 8910278
references: Eur J Heart Fail. 2007 Aug;9(8):795-801
references: 17693380
references: Cardiovasc Diabetol. 2012 Mar 21;11:26
references: 22433902
references: Circulation. 2008 Nov 11;118(20):2057-62
references: 18955667
references: J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63
references: 16376782
references: Circulation. 2007 Mar 27;115(12):1537-43
references: 17389279
references: Atherosclerosis. 2010 Jul;211(1):164-9
references: 20193950
references: Atherosclerosis. 2007 Nov;195(1):e150-8
references: 17553506
references: Diab Vasc Dis Res. 2009 Jul;6(3):153-63
references: 20368207
references: J Lipid Res. 2008 Aug;49(8):1746-51
references: 18421072
references: Circulation. 2004 Oct 12;110(15):2168-74
references: 15451800
references: Atherosclerosis. 2008 Jul;199(1):147-53
references: 17983623
references: J Am Coll Cardiol. 2010 Jan 26;55(4):283-93
references: 20117431
references: J Card Fail. 2008 Sep;14(7):615-25
references: 18722328
references: Clin Chem. 2008 Jan;54(1):181-7
references: 18024526
references: J Card Fail. 2004 Jun;10(3):228-35
references: 15190533
references: Eur J Heart Fail. 2013 Apr;15(4):394-9
references: 23223158
references: Clin Sci (Lond). 2013 Jan;124(2):115-22
references: 23013043
references: Nat Rev Drug Discov. 2008 Jun;7(6):489-503
references: 18511927
references: Diabetes. 1999 Oct;48(10):1987-94
references: 10512363
references: Diabetes Care. 2007 Oct;30(10):2667-72
references: 17620449
references: Atherosclerosis. 2010 Nov;213(1):329-31
references: 20723896
references: Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2327-35
references: 22679309
references: Ann Intern Med. 1999 Mar 16;130(6):461-70
references: 10075613
references: J Card Fail. 2011 May;17(5):374-80
references: 21549293
references: Cardiovasc Diabetol. 2012 Jun 18;11:72
references: 22709426
references: Nat Med. 2001 Jun;7(6):699-705
references: 11385507
references: J Am Coll Cardiol. 2009 Dec 29;55(1):53-60
references: 20117364
references: Clin Chem. 2006 Mar;52(3):405-13
references: 16423904
references: Eur Heart J. 2002 Jun;23(11):886-91
references: 12042010
references: Gynecol Endocrinol. 2011 Nov;27(11):935-9
references: 21605000
references: Eur Heart J. 2008 Oct;29(19):2388-442
references: 18799522